Lantern Pharma Inc. hosted a September 23, 2026 webinar focused on its Open-Medicine AI multi-agentic platform for drug development. Investors can access the replay through YouTube and Lantern Pharma’s investor website, while the accompanying presentation offers the company’s discussion materials for review.
Key Highlights
- Lantern Pharma Inc. held a live webinar on September 23, 2026, focused on its Open-Medicine AI platform.
- The discussion covered a multi-agentic AI platform intended for drug development.
- A webinar replay is available through YouTube and Lantern Pharma’s investor website.
Lantern Pharma Inc. (NASDAQ: LTRN) is a Pharmaceuticals: Major company. The company hosted a live webinar on September 23, 2026, focused on its Open-Medicine AI multi-agentic platform for drug development. The presentation used during the discussion is also available as supporting material.
Open-Medicine AI Platform Discussion
The presentation used to support the webinar discussion is available alongside the event materials. That presentation covers the subject of the Open-Medicine AI platform.
FAQs
Q: What did Lantern Pharma discuss in its September 23 webinar?
A: The live webinar took place on September 23, 2026.
Q: Where can investors watch the Lantern Pharma webinar replay?
A: The Lantern Pharma webinar replay is available through YouTube and the investor section of the company’s website. Both provide access to the recorded discussion.
Q: What materials accompany the Open-Medicine AI webinar?
A: Lantern Pharma made the presentation used during the webinar discussion available with the event materials. It relates to the Open-Medicine AI platform.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.